Literature DB >> 19725016

Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters.

Guoxiang Shen1, Ah-Ng Kong.   

Abstract

The nuclear transcription factor E2-related factor 2 (Nrf2) has been shown to play pivotal roles in preventing xenobiotic-related toxicity and carcinogen-induced carcinogenesis. These protective roles of Nrf2 have been attributed in part to its involvement in the induction of Phase II drug conjugation/detoxification enzymes as well as antioxidant enzymes through the Nrf2-antioxidant response element (ARE) signaling pathways. This review summarizes the current research status of the identification of Nrf2-regulated drug metabolism enzymes (DMEs), especially Phase II DMEs, and Phase III drug transporters. In addition, the molecular mechanisms underlying the coordinated regulation of Phase II DMEs and Phase III transporters will also be discussed based on findings published in the literature. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725016      PMCID: PMC2782863          DOI: 10.1002/bdd.680

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  58 in total

1.  Induction of hepatic antioxidant enzymes by phenolic acids in rats is accompanied by increased levels of multidrug resistance-associated protein 3 mRNA expression.

Authors:  Chi-Tai Yeh; Gow-Chin Yen
Journal:  J Nutr       Date:  2006-01       Impact factor: 4.798

2.  Functional antioxidant responsive elements.

Authors:  W W Wasserman; W E Fahl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes.

Authors:  Weimin Miao; Lianggao Hu; P James Scrivens; Gerald Batist
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

4.  Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver.

Authors:  Jonathan M Maher; Xingguo Cheng; Angela L Slitt; Matthew Z Dieter; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-04-15       Impact factor: 3.922

Review 5.  Induction of phase I, II and III drug metabolism/transport by xenobiotics.

Authors:  Changjiang Xu; Christina Yong-Tao Li; Ah-Ng Tony Kong
Journal:  Arch Pharm Res       Date:  2005-03       Impact factor: 4.946

Review 6.  Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents.

Authors:  Guoxiang Shen; Woo-Sik Jeong; Rong Hu; Ah-Ng Tony Kong
Journal:  Antioxid Redox Signal       Date:  2005 Nov-Dec       Impact factor: 8.401

7.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

8.  Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways.

Authors:  Xingguo Cheng; Jonathan Maher; Matthew Z Dieter; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-05-26       Impact factor: 3.922

Review 9.  Nrf2 as a novel molecular target for chemoprevention.

Authors:  Jeong-Sang Lee; Young-Joon Surh
Journal:  Cancer Lett       Date:  2004-11-11       Impact factor: 8.679

Review 10.  Regulation of hepatic transporters by xenobiotic receptors.

Authors:  C D Klaassen; A L Slitt
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

View more
  59 in total

1.  Isothiocyanate-drug interactions in the human adenocarcinoma cell line Caco-2.

Authors:  Katarzyna Lubelska; Irena Misiewicz-Krzemińska; Małgorzata Milczarek; Jolanta Krzysztoń-Russjan; Elżbieta Anuszewska; Karolina Modzelewska; Katarzyna Wiktorska
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

2.  Understanding transport through pharmacological barriers--are we there yet?

Authors:  Balázs Sarkadi; Gergely Szakács
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 3.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

4.  Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice.

Authors:  John D Clarke; Anna Hsu; David E Williams; Roderick H Dashwood; Jan F Stevens; Masayuki Yamamoto; Emily Ho
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

Review 5.  Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer.

Authors:  Constance Lay Lay Saw; Ah-Ng Tony Kong
Journal:  Expert Opin Ther Targets       Date:  2011-01-25       Impact factor: 6.902

6.  Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates.

Authors:  Constance Lay-Lay Saw; Melvilí Cintrón; Tien-Yuan Wu; Yue Guo; Ying Huang; Woo-Sik Jeong; Ah-Ng Tony Kong
Journal:  Biopharm Drug Dispos       Date:  2011-06-08       Impact factor: 1.627

7.  Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY.

Authors:  Gabriel Bendavit; Tahar Aboulkassim; Khalid Hilmi; Sujay Shah; Gerald Batist
Journal:  J Biol Chem       Date:  2016-10-26       Impact factor: 5.157

Review 8.  Chemical modulation of transcription factors.

Authors:  Bianca Wiedemann; Jörn Weisner; Daniel Rauh
Journal:  Medchemcomm       Date:  2018-07-11       Impact factor: 3.597

9.  Enhanced phase II detoxification contributes to beneficial effects of dietary restriction as revealed by multi-platform metabolomics studies.

Authors:  He Wen; Hye-Ji Yang; Yong Jin An; Joon Mee Kim; Dae Hyun Lee; Xing Jin; Sung-Woo Park; Kyung-Jin Min; Sunghyouk Park
Journal:  Mol Cell Proteomics       Date:  2012-12-09       Impact factor: 5.911

10.  Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.

Authors:  Raffaela Barbano; Lucia Anna Muscarella; Barbara Pasculli; Vanna Maria Valori; Andrea Fontana; Michelina Coco; Annamaria la Torre; Teresa Balsamo; Maria Luana Poeta; Giovanni Francesco Marangi; Evaristo Maiello; Marina Castelvetere; Fabio Pellegrini; Roberto Murgo; Vito Michele Fazio; Paola Parrella
Journal:  Epigenetics       Date:  2012-12-18       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.